Emily E. Bosco: Leaving Alliance for Cancer Gene Therapy 2025 Summit feeling inspired
Emily E. Bosco, Senior Director in Cell Therapy, Early oncology at AstraZeneca, shared a post on LinkedIn:
“I am leaving Alliance for Cancer Gene Therapy 2025 Summit feeling inspired!
It’s a truly exciting time for the advancement of cell therapies in oncology, and connecting with so many experts in the field has reinforced why.
My highlight was joining the keynote panel on ‘The Current Pharma Perspective on Cancer Immunotherapy’, where we explored important topics such as the future of cell therapies, potential challenges and advancements in personalized treatments.
Thanks to the other panel members george yancopoulos, Ruth Salmon, Ira Mellman and moderator Greg Simon for such an interesting discussion.
At AstraZeneca, we are committed to realizing the transformative potential of cell therapies for people living with cancer. We are making this happen through our end-to-end approach that is facilitating innovation and building the infrastructure necessary to bring next-generation cell therapies to patients.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023